Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.remnie.2025.500126 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Meta-analysis of 68Ga-FAPI PET in Assessment of Ovarian Cancer.
Acad Radiol
March 2025
Department of Nuclear Medicine, Beijing Luhe Hospital, Capital Medical University, Xinhua Road 82, Tong Zhou District, 101199 Beijing, China.
Rationale And Objectives: The objective of this research is to carry out a systematic review and meta-analysis to detect the diagnostic efficacy of 68Ga-FAPI Positron Emission Tomography (PET) Computed Tomography/Magnetic Resonance (CT/MR) in total of the lesions as well as different aspects of metastasis in individuals with ovarian cancers (OC).
Materials And Methods: The PubMed, Embase, Cochrane library, and Web of Science databases were thoroughly searched until the cut-off date of July 23, 2024. The assessment of 68Ga-FAPI PET CT/MR of OC was presented by the included studies.
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?
Ann Nucl Med
March 2025
Department of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), Logroño, La Rioja, Spain.
[F]FDG PET/CT is the most widely used PET radiopharmaceutical in oncology, but it is not exempt of diagnostic limitations. FAPI have emerged as a great tool in the management of several different solid tumours in which [F]FDG is not able to provide enough information. The aim of this work was to evaluate the available evidence on diagnostic and therapeutic applications of PET/CT with FAPI radiopharmaceuticals.
View Article and Find Full Text PDFThe Role of AI in Lymphoma: An Update.
Semin Nucl Med
March 2025
Faculty of Medicine, University of Leeds, Leeds LS2 9JT, England; Department of Radiology, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, LS9 7TF, England. Electronic address:
Malignant lymphomas encompass a range of malignancies with incidence rising globally, particularly with age. In younger populations, Hodgkin and Burkitt lymphomas predominate, while older populations more commonly experience subtypes such as diffuse large B-cell, follicular, marginal zone, and mantle cell lymphomas. Positron emission tomography/computed tomography (PET/CT) using [F] fluorodeoxyglucose (FDG) is the gold standard for staging, treatment response assessment, and prognostication in lymphoma.
View Article and Find Full Text PDFHead-to-Head comparison of [F]FES and [F]FDG PET/CT in breast cancer patients: has a new era come?
Eur J Nucl Med Mol Imaging
March 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Purpose: This review systematically compared, in a head-to-head manner, the diagnostic and prognostic performance of [F]FDG and [F]FES PET/CT in breast cancer (BC) patients.
Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science databases up to January 2025, without temporal limitations or restrictions on the number of patients in the included studies, to identify relevant articles comparing the diagnostic value of [F]FDG and [F]FES PET in BC patients. Selected imaging studies were analyzed using a modified version of the Critical Appraisal Skills Programme checklist dedicated to systematic reviews.
Pancreatic ductal adenocarcinoma (PDAC) is highly susceptible to metastasis, making early detection of metastases and associated risk factors crucial for effective management. This study aimed to assess the performance of fluorine (F)- fibroblast activation protein inhibitor-04 (F-FAPI-04) positron emission tomography/computed tomography (PET/CT) in detecting metastasis and predicting pathological characteristics and risk factors in 67 PDAC patients. Comparisons were made with F-fluorodeoxyglucose (F-FDG) PET/CT.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!